B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

APEX1

MOLECULAR TARGET

apurinic/apyrimidinic endodeoxyribonuclease 1

UniProt: P27695NCBI Gene: 3286 compounds

APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting APEX1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tanshinone iia3.7441
2thiolactomycin3.0921
3mitoxantrone hydrochloride2.309
4lucanthone2.208
5Aurintricarboxylic Acid1.393
6myricetin-3-O-galactopyranoside [Supplementary Concept]1.102

About APEX1 as a Drug Target

APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented APEX1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

APEX1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.